The impact of funding cuts on medical research is profound and far-reaching, threatening not only scientific advancements but also the very safety of patients enrolled in clinical trials.As federal research grants dwindle, crucial oversight mechanisms, governed by Institutional Review Boards (IRBs), face severe disruptions.